Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Female, age ≥18 years, signed informed consent.~2. Eastern Cooperative Oncology Group (ECOG) performance status 0-2~3. Patients must have a life expectancy of at least 3 months.~4. Histologically or pathologically confirmed diagnosis of epithelial carcinoma of the ovary. Failure of at least two-line chemotherapy OR platinum resistant ovarian cancer (defined as relapsing within 6 months after a platinum based chemotherapy) OR platinum refractory ovarian cancer (defined as progressing during a platinum based chemotherapy).~5. Criteria for recurrence or metastasis: blood CA125 is more than 2 times the upper limit of normal value, or imaging findings (CT/MRI/PET-CT) show recurrence or metastasis, or ascites cancer cells are positive.~6. Platinum refractory or resistant criteria: relapse or metastasis within 6 months end of platinum based chemotherapy.~7. The interval time to last chemotherapy was more than 4 weeks.~8. The patient received radiotherapy or surgery for more than 4 weeks, and the wound healed completely.~9. Patients must have adequate organ function as defined by the following criteria: White blood cell count ≥ 3 x 10\^9/L, Absolute neutrophil count (ANC) (≥ 1.0 x 10\^9/L), Hemoglobin of ≥ 80 g/L, Platelets ≥ 70 x 10\^9/L. Total bilirubin ≤ 1 x upper limit of normal (ULN), AST and ALT ≤ 2 x ULN. Serum creatinine ≤ 1 x ULN~10. The main organs (liver, kidney and heart) function are basically normal.~Exclusion Criteria:~1. Had prior exposure to apatinib or has known allegies to apatinib.~2. History of other malignant tumors (except those with cured basal cell carcinoma and cervical carcinoma in situ).~3. History of myocardial infarction, or unstable angina, or New York Heart Association (NYHA) Grade III-IV within 6 months prior to Day 1.~4. Patients with QT interval prolongation.~5. Inadequately controlled hypertension.~6. Serious, non-healing wound, active ulcer, bowel obstruction.~7. History of abdominal fistula or gastrointestinal perforation within 28 days prior to Day 1.~8. Evidence of bleeding diathesis or coagulopathy.~9. Patients with positive urine protein.~10. Major surgical procedure within 28 days prior to Day 1.~11. Symptomatic central nervous system (CNS) metastasis.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- apatinib (Type: EXPERIMENTAL): 1 times a day, atapinib, 500 mg, is taken orally

Based on this trial design, predict the completion outcome and termination type (if applicable).